SEC Form 4 · accession 0001055726-16-000027
INOVIO PHARMACEUTICALS, INC. · INO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jong Joseph Kim
Officer — Chief Executive Officer · Director
Period of report
Mar 9, 2016
Accepted (ET)
Mar 11, 2016 · 4:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001055726
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock OptionF1 | $7.02 | Mar 9, 2016 | A | 172,000 | A | Mar 9, 2016 | Mar 9, 2026 | Common Stock | 172,000 | 172,000 | D |
| Restricted Stock UnitF2 | — | Mar 9, 2016 | A | 172,000 | A | — | — | Common Stock | 172,000 | 172,000 | D |
Explanation of responses
- F1The vesting schedule for the 172,000 options is as follows: 43,000 shares vested on March 9, 2016; 43,000 shares will vest on March 9, 2017; 43,000 shares will vest on March 9, 2018; 43,000 shares will vest on March 9, 2019.
- F2Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units is as follows: 57,334 shares will vest on March 9, 2017; 57,333 shares will vest on March 9, 2018; 57,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.